2026-10-25
Celcuity clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 26,990 +1.35%
S&P 7,377 +0.31%
GOLD $4,075 −0.94%
BTC $75,677 −0.09%
VIX 25.64 −9.01%
latest tape · as of 20:08 UTC
The Screen · Healthcare · Biotechnology
Celcuity Inc.
CELC · Nasdaq · USD · Market cap $3.4B · 155 employees
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.
Not yet scored66.79 USD
Price as of 6 Nov 2026Daily close, not a live quote
Screened 2026-11-06 · the tape above runs as of 20:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price66.79 USD at the 6 Nov 2026 close
- Fair valueUnder review: our model's value is 2.26x the price, above our 2.00x limit.
- Our regime readMarkdown, as of 7 Nov 2026
- Ethical screenNot yet scored
- OptionsOpen interest leans slightly to calls (put/call 0.74)
- Last reviewed6 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: range not available (screen dated 2026-11-06).
- Trend Markdown
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.74, read 2026-11-05
- Ethical screen not yet scored
Price66.79 USD
Fair valueUnder review
Ethical score95.6/100
Our investment reviews on this name
2026-11-01Read Markdown69.13-3.4% to today ✓Distribution gives way to Markdown after a 21% rise in 4 days
2026-10-28Read Distribution57.12+16.9% to today Markdown gives way to Distribution after a 26% slide in 4 weeks
2026-10-02Read Markdown77.38-13.7% to today ✓Markup gives way to Markdown after a 12% slide in 13 weeks
2026-07-02Read Markup88.28-24.3% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its markdown label.
Celcuity Inc. holds its Markdown at $66.79. Elevated stress, defensive posture warranted, held for 56 days.
| Phase | Markdown · caution |
| Quantitative state | Elevated stress, defensive posture warranted, held for 56 days |
| Price at the screen | $66.79 |
| Valuation | N/A trailing · -871.50 forward price to earnings |
| Values screen | Not scored · score 95.6 |
| Beta | 0.13 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 4.94% | Below 33% | Interest-bearing debt is just 4.9% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 6.78% | Below 33% | Cash held in interest-bearing accounts and securities is 6.8% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Celcuity clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Celcuity clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 5%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value under review. Our model's value is 2.26x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
How a fair value is estimated: discounted cash flow (DCF).
The Street's RangeThird-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +126% from the screen price.
Where our models see it going: no fair-value estimate yet, range not available, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsBiotech bet on one drug hits fair value
Picture a lab team pinning everything on one molecule that might slow aggressive tumours. Celcuity has reached that point with Gedatolisib yet still burns cash and shows no profit, so the shares trade right at our calculated worth with almost no margin of safety.
The market already hands the stock a strong buy label and a much higher target price, yet the forward multiple sits above 92 times while return on equity remains deeply negative. Ethical screens clear the company, which removes one usual reason to step aside, but the business remains a pure clinical bet.
Risks sit in plain sight: zero current earnings, heavy dilution ahead and the usual late-stage trial failures that can wipe out most of the value overnight. At current levels the price simply matches the numbers rather than offering any cushion. Analysis, not advice.
| Forward P/E | -871.5x |
| EPS, trailing | -4.31 |
| EPS, forward | -0.08 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -1,433.7%not currently earning a positive return on equity |
| FCF yield | -2.11% |
| Current ratio | 8.93comfortably covers its short-term bills |
| Beta | 0.13barely tracks the market's swings |
| Short interest, float | 0.31% |
| 52-week range | 53.54 - 151.02 |
| Market cap | $3.4B |
| Employees | 155 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeCELC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Markdown $69.24
-0.7% Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.7% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Markdown $69.72
+0.9% Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Markdown $69.13
+0.0% Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Markdown $69.13
+0.0% Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Markdown · changed $69.13
-0.5% Entry 12
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.5% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Distribution $69.46
+0.0% Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Distribution $69.46
+21.6% Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 21.6% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28
Distribution · changed $57.12
+0.0% Entry 9
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-10-21
Markdown $57.12
-15.9% Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 15.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
2026-10-14
Markdown $67.94
-12.2% Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.2% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 44% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 588%. Our forward projection puts the odds of a 10% gain over the next month near 47%. The street (11 analysts) rates it strong buy, with a mean price target of $169.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call Yahoo Finance · 9d ago
- Will Breast And Prostate Cancer Data Change Celcuity (CELC) Narrative Yahoo Finance · 13d ago
- Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026 Yahoo Finance · 15d ago
- Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026 Yahoo Finance · 15d ago
- Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
NRIXNurix Therapeutics, Inc.
ATAIAtaiBeckley Inc.
ZLABZai Lab Limited
IRONDisc Medicine, Inc.
MRVIMaravai LifeSciences Holdings, Inc.
DNLIDenali Therapeutics Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-19 | BULLER RICHARD E | Director | 1,029 | · | |
| 2026-05-04 | DALVEY DAVID F | Director | 25,000 | $3,517,000 | |
| 2026-05-04 | BULLER RICHARD E | Director | 9,000 | $1,264,181 | |
| 2026-05-04 | BULLER RICHARD E | Director | 9,000 | $45,900 | |
| 2026-04-09 | NIGON RICHARD J | Director | 10,000 | · | |
| 2026-03-31 | BULLER RICHARD E | Director | 3,000 | $330,804 | |
| 2026-03-31 | BULLER RICHARD E | Director | 3,000 | $15,300 | |
| 2026-02-11 | ROMP CHARLES R | Director | 215 | · | |
| 2026-01-27 | DALVEY DAVID F | Director | 20,000 | $2,400,538 | |
| 2025-12-15 | NIGON RICHARD J | Director | 19,975 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $125.64 | -29.2% | · | $708 | -29.2% |
| 2 months | $117.14 | -24.1% | · | $759 | -24.1% |
| 3 months | $110.77 | -19.7% | · | $803 | -19.7% |
| 6 months | $100.77 | -11.7% | · | $883 | -11.7% |
| 1 year | $12.92 | +588.5% | · | $6,885 | +588.5% |
| 2 years | $14.23 | +525.1% | · | $6,251 | +525.1% |
| 3 years | $11.11 | +700.6% | · | $8,006 | +700.6% |
| 5 years | $26.90 | +230.7% | · | $3,307 | +230.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CELC does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.